References
- M Schiffman, PE Castle, J Jeronimo. Human papillomavirus and cervical cancer. Lancet. 370(9590): 2007; 890–907.
- JM Partridge, LA Koutsky. Genital human papillomavirus infection in men. Lancet Infectious Diseases. 6(1): 2006; 21–31.
- National Health Service. Q&A on HPV vaccines. At: <www.immunisation.nhs.uk/files/HPV_Q&A.pdf. >. Accessed 1 June 2008.
- Z Kmietowicz. Choice of cancer vaccine is branded a missed opportunity by charities. BMJ. 336: 2008; 1456–1457.
- FPA. FPA statement on new cervical cancer vaccine. 18 June 2008. At: <www.fpa.org.uk/news/press/current/detail.cfm?contentID=1005. >. Accessed 28 September 2008.
- AR Giuliano. Human papillomavirus vaccination in males. Gynecologic Oncology. 107: 2007; S24–S26.
- AT Newall, P Beutels, JG Wood. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infectious Diseases. 7(4): 2007; 289–296.
- Public Health and Wellbeing Directorate. Implementation of Immunisation Programme: Human Papilloma Virus (HPV) Vaccine – Project Update including the Catch Up Campaign. 6 February 2008. At: <www.sehd.scot.nhs.uk/mels/CEL2008_05.pdf. >. Accessed 1 June 2008.
- JJ Kim. Human papillomavirus vaccination in the UK. BMJ. 337: 2008; a842.
- M Jit, YH Choi, WJ Edmunds. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 337: 2008; a769.
- NHS. Q+A on HPV vaccines. 2007. At: <www.immunisation.nhs.uk/files/HPV_Q&A.pdf. >. Accessed 4 October 2008.
- EF Dunne, CM Nielson, KM Stone. Prevalence of HPV infection among men: a systematic review of the literature. Journal of Infectious Diseases. 194: 2006; 1044–1057.
- MCG Bleeker, CJ Hogewoning, J Berkhof. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clinical Infectious Diseases. 41: 2005; 612–620.
- WHO/ICO Information Centre on HPV and Cervical Cancer. Human Papillomavirus and Cervical Cancer. 2007. At: <www.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/GBR.pdf?CFID=278048&CFTOKEN=18959369. >. Accessed 4 October 2008.
- M Jit, A Vyse, R Borrow. Prevalence of human papillomavirus antibodies in young female subjects in England. British Journal of Cancer. 97: 2007; 989–991.
- Sanofi Pasteur MSD Limited. Gardasil. 26 February 2008. At: <www.emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=19016. >. Accessed 1 June 2008.
- ClinicalTrials.gov. An Investigational Study of Gardasil (V501) in Reducing the Incidence of Anogenital Warts in Young Men. At: <www.clinicaltrials.gov/ct2/show/NCT00090285?term=Gardasil+young+men&rank=1. >. Accessed 1 June 2008.
- SL Block, T Nolan, C Sattler. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Paediatrics. 118: 2006; 2135–2145.
- EH Elbasha, EJ Dasbach, RP Insinga. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Diseases. 13(1): 2007; 28–41.
- GP Garnett. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. Journal of Infectious Diseases. 191: 2005; S97–S106.
- JP Hughes, GP Garnett, L Koutsky. The theoretical population-level impact of a prophylactic human papillomavirus vaccine. Epidemiology. 13(6): 2002; 631–639.
- Anon Should HPV vaccines be mandatory for all adolescents?. Lancet. 368: 2006; 1212.
- M Böttiger, M Forsgren. Twenty years’ experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine. 15(14): 1997; 1538–1544.
- AJ Vyse, NJ Gay, JM White. Evolution of surveillance of measles, mumps and rubella in England and Wales: providing the platform for evidence-based vaccination policy. Epidemiologic Reviews. 24: 2002; 125–136.
- FX Bosch, X Castellsague, N Munoz. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. Journal of National Cancer Institute. 88: 1996; 1060–1067.
- EI Svare, SK Kjaer, AM Worm. Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sexually Transmitted Infections. 78: 2002; 215–218.
- AM Johnson, CH Mercer, B Erens. Sexual behaviour in Britain: partnerships, practices and HIV risk behaviours. Lancet. 358: 2001; 1835–1842.
- Health Protection Agency. Genital warts statistics. 26 February 2008. At: <www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1195733781837. >. Accessed 16 May 2008.
- CN Nielson, RB Flores, M Harris. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiololgy Biomarkers and Prevention. 16: 2007; 1107–1114.
- MJ Campion, A Singer, PK Clarkson. Increased risk of cervical neoplasia in consorts of men with penile condylomata acuminate. Lancet. 1: 1985; 943–946.
- LL Villa. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine. 24(S1): 2006; 23–28.
- Joint Committee on Vaccination and Immunisation. Minutes of the HPV Sub-group meeting, Tuesday, 23 May 2006. 6 March 2008. At: <http://advisorybodies.doh.gov.uk/jcvi/mins-hpv-230506.htm. >. Accessed 1 June 2008.
- DM Parkin, F Bray. Chapter 2: The burden of HPV-related cancers. Vaccine. 24(S3): 2006; 11–25.
- M Frisch, C Fenger, AJ van den Brule. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomavirus. Cancer Research. 59: 1999; 753–757.
- Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006;24:S3/140–46.
- G D’Souza, AR Kreimer, R Viscidi. Case-control study of human papillomavirus and oropharyngeal cancer. New England Journal of Medicine. 356: 2007; 1944–1956.
- ML Gillison. Human papillomavirus-associated head and neck cancer in a distinct epidemiologic, clinical, and molecular entity. Seminars in Oncology. 31(6): 2004; 744–754.
- J Mork, AK Lie, E Glattre. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 344: 2001; 1125–1131.
- Cancer Research UK. UK Oral Cancer Statistics. August 2007. At: <http://info.cancerresearchuk.org/cancerstats/types/oral?a=5441. >. Accessed 16 May 2008.
- Cancer Research UK. Definite risks for mouth and oropharyngeal cancer. July 2008. At: <http://www.cancerhelp.org.uk/help/default.asp?page=13053. >. Accessed 4 October 2008.
- JJ Goedert, TR Cote, P Virgo. Spectrum of AIDS-associated malignant disorders. Lancet. 351: 1998; 1833–1839.
- JM Palefsky, EA Holly, ML Ralston. Prevalence and risk factors for human papillomavirus infection in the anal canal in HIV-positive and HIV-negative homosexual men. Journal of Infectious Diseases. 177: 1998; 361–367.
- M Frisch, RJ Biggar, JJ Goedert. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. Journal of National Cancer Institute. 92: 2000; 1500–1510.
- C Piketty, TM Darragh, M Da Costa. High prevalence of anal human papillomavirus infection in anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Annals of Internal Medicine. 183: 2003; 453–459.
- Cancer Research UK. Risks and causes of anal cancer. March 2008. At: <http://www.cancerhelp.org.uk/help/default.asp?page=20808. >. Accessed 4 October 2008.
- M Roberts. Gay men seek “female cancer” jab. BBC News. 23 February 2007. At: <http://news.bbc.co.uk/1/hi/health/6342105.stm. >. Accessed 1 December 2007.
- L Udesky. Push to mandate HPV vaccine triggers backlash in USA. Lancet. 369(9566): 2007; 979–980.
- P Boynton. HPV Vaccine - will be introduced in the UK for girls only. 26 October 2007. At: <www.drpetra.co.uk/blog/?p=573. >. Accessed 1 December 2007.
- I Ndong, WR Finger. Male responsibility for reproductive health. Network. 18(3): 1998; 4–6.